Elisabetta Bonzano MD, PhD
@to_be_elizabeth
Radiation Oncologist, MD, PhD Fondazione IRCCS Policlinico San Matteo @UniPv - MIUR Qualified Associate Professor - PhD in Experimental Medicine
🚨🔝🔟 Abtracts to be presented at #ASCO24 by @OncoAlert 🚨 #OncoAlertAF #breastcancer
Dear Colleagues, The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 This List Curated by: #OncoAlertAF Leads : @ElisaAgostinett 🇧🇪 @to_be_elizabeth 🇮🇹 @weoncologists 🇺🇸 With our distinguished OncoAlert Faculty: @ErikaHamilton9 🇺🇸 @DrSGraff…
📌 Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer 🔗aacrjournals.org/clincancerres/… @OncoAlert #OncoAlertAF @AACR
🔺REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ‼️📩 👉🏻The @OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 Discussing: 🧬 ✅HER2DX & survival in early HER2+ #breastcancer ✅GIM12-TYPHER Trastuzumab plus lapatinib or…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER) buff.ly/UrXfLEu In this open-label, phase II trial of pretreated HER2-positive advanced #BreastCancer , trastuzumab plus…
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis buff.ly/1loYQqK A comprehensive individual patient-level meta-analysis of over 2,500 patients from 11 studies demonstrated that the HER2DX genomic test…
👉🏻oncoalert.m-pages.com/nhMpwe/oncoale…‼️📩📩📩 The @OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 📆 Discussing: ✅POSITIVE Trial in #BreastCancer 🔗ascopubs.org/doi/abs/10.120…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…
📌 Repositioning Radiation Oncology at the centre of integrated oncology care: A manifesto of the European Society for Radiotherapy and Oncology (ESTRO) 🔗sciencedirect.com/science/articl… ✨ to reposition radiation oncology not simply as a treatment modality, but as a strategic,…
📌 HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 🔗 thelancet.com/journals/lanon… ✨ HER2DX provides clinically meaningful prognostic stratification in early-stage HER2-positive breast cancer, beyond standard…
📌 Dual blockade of PD-1 and CTLA-4 generates long-lasting immunity against irradiated glioblastoma 🧠 🔗 sciencedirect.com/science/articl… 👉🏻Irradiated glioblastoma cells accumulate dsDNA and release IFN-I signals. 👉🏻5 × 6Gy radiation induces optimal IFN-I response and improves…
📌 Genomic landscape of hormone therapy‑resistant HR‑positive, HER2‑negative breast cancer 🧬 What drives hormone therapy resistance in HR+/HER2− breast cancer? A new study dives deep into genomics, clonal evolution, and the role of ctDNA in predicting relapse. 🔗…
👉🏻REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… 📩📩📩 ‼️The @OncoAlert 🚨Weekly Round Up Covering the TOP of the week July 4-10, 2025‼️ Discussing: ✅News From Industry: durvalumab in #BladderCancer ✅PRIM-B in metastatic #BreastCancer ✅Breastfeeding…
The OncoAlert🚨Weekly Round Up Covering the TOP of the week July 4-10, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅News From Industry: durvalumab in #BladderCancer ✅PRIM-B in metastatic #BreastCancer ✅Breastfeeding after breast…
The @OncoAlert @VJOncology JOURNAL CLUB This week we have the pleasure to bring you @Icro_Meattini 🇮🇹of the University of Florence Discussing: Multimodal De-Escalation Strategies in Early Breast Cancer on the @ASCO Educational Book Direct Link to Publication…
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial buff.ly/Fmhuyub In a randomized study of 407 patients with de novo stage IV #BreastCancer , primary tumor…
‼️REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… 📩📩📩 ➡️The @OncoAlert 🚨Newsletter Now Out !! Covering June 23-July 3, 2025 🗓️ Discussing: ✅ShortHER in #BreastCancer and more ⤵️
The OncoAlert🚨Newsletter Now Out !! Covering June 23-July 3, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅Update on FORTITUDE-101 (Industry) GEJ ✅ShortHER in #BreastCancer ✅U-BOMB Trial in Breast #Cancer ✅DADSPORT in…
📌 Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials of the Last Decade 🔗 ascopubs.org/doi/10.1200/GO… #Oncology #BreastCancer #HealthEquity @OncoAlert #OncoAlertAF @JCOGO_ASCO
📌 Inavolisib-Based Triplet Therapy for PIK3CA-Mutated Hormone Receptor+/HER2- Breast Cancer: Clinical Implications and Practical Considerations 🔗 ascopubs.org/doi/pdf/10.120… @OncoAlert #OncoAlertAF @DFCI_BreastOnc @stolaney1 @elmayermd @GuiNaderMarta
We’re excited to welcome the new and returning members of BIG’s Executive Board, starting 1 July 2025! Thank you to our outgoing members for their incredible dedication and leadership. Together, we continue advancing international breast cancer research. 💗
Welcome to @OncoAlert 🚨 #GynOnc Week Today we have TOP Trials in #EndometrialCancer with Dr. Annamaria Ferrero 🇮🇹& Dr @AStrojnaMD 🇩🇪 @CoquardRay @NicoloBizzarri @ChargariC @CF_PC_OvCaGroup @ESGO_society @EngageEsgo @agz_eriksson @womenofteal @ENYGO_official @IJGConline…
📌 Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline 🔗 practicalradonc.org/article/S1879-… @OncoAlert #OncoAlertAF #RadOnc
